Pill Form GLP-1 Drug Shows Promise for Weight Loss in Clinical Trial

A new oral medication is shaking up the weight loss treatment landscape. In a phase II clinical trial published in Nature Medicine, aleniglipron helped adults with obesity or overweight lose as much as 12 percent of their body weight over 36 weeks. Unlike current GLP-1 drugs that require injections, this small-molecule approach could make obesity treatment more accessible to millions of people.

Dr. Robert Kushner, professor emeritus of Medicine at Northwestern University and a co-author of the study, highlights what makes this different: aleniglipron works like existing GLP-1 treatments but comes in pill form.

Why This Matters for Patients

Current GLP-1 medications like semaglutide (Ozempic and Wegovy) have proven remarkably effective at helping people lose weight. They work by mimicking a naturally occurring hormone that stimulates insulin secretion, reduces appetite, and increases feelings of fullness. The problem? Access remains limited for many patients.

Injectable medications create multiple barriers. They require refrigeration, which complicates storage and travel. Manufacturing at scale has proven difficult and expensive. Perhaps most importantly, the injection requirement itself deters many potential patients who prefer taking pills.

Small-molecule drugs like aleniglipron address these limitations head-on. “The difference with aleniglipron is it’s a small molecule, which means it’s chemically made and could be taken with or without food,” Kushner explained. “Most medications we take, whether it’s aspirin or blood pressure medicine, are small molecules. Because of that you can potentially combine them with other medications.”

How the Trial Worked

Researchers evaluated 230 adults with an average age of 50 across 38 U.S. medical centers. Participants received one of three doses (45, 90, or 120 milligrams) or placebo, taking the medication orally once daily with doses increased every four weeks over 36 weeks.

The results were dose-dependent and encouraging. The 45-milligram group lost 9 percent of body weight. The 90-milligram group achieved 10.7 percent weight loss. The highest dose of 120 milligrams produced 12.1 percent weight loss. The placebo group saw only 0.5 percent change.

Safety and Tolerability

The safety profile looked solid. Gastrointestinal side effects, common with GLP-1 medications, were generally mild to moderate and actually decreased over time as the trial progressed. Only 10.4 percent of participants discontinued treatment. Importantly, researchers found no cases of drug-induced liver injury or other serious safety concerns.

“We didn’t find any concerns; no new safety signals,” Kushner said. “We found a dose that seems to be effective, and the dose escalation will be slowed down further as we go into phase III trial to increase tolerability.”

What’s Next

These promising results support moving forward to phase III trials, where efficacy will be tested in larger patient populations over longer periods. The slower dose escalation going forward should help patients adjust better to the medication.

If aleniglipron continues performing well, it could transform obesity treatment by offering an affordable, accessible oral alternative to current injectable options. This could be particularly significant given the growing obesity epidemic and the potential for personalized medicine approaches in weight management.

The real question isn’t whether we can treat obesity effectively anymore. It’s whether we can make that treatment available to everyone who needs it.

Source: Northwestern Medicine